Sichuan 3D bioprinting blood vessels successfully achieved global breakthrough in monkey experiments December 13, 2016 Source: Huaxi Dushi Bao Blu-ray Development Holdings subsidiary Sichuan Blu-ray Yingnuo Biotechnology Co., Ltd. (hereinafter referred to as “Blu-ray Yingnuoâ€) held a results conference to announce the success of the Blu-ray Inno 3D bio-printing blood vessel implanted rhesus monkey in vivo, which marked the trouble The half-century clinical vascular endothelialization problem has successfully found a solution, bringing the gospel to nearly 1.8 billion patients with cardiovascular disease worldwide. In October last year, Blu-ray Inno released the world's leading 3D biovascular printer. Nowadays, printing blood vessels has become a reality, and animal experiments have been successful. This means that Chengdu 3D bio-printing has achieved major technological breakthroughs in the world. The first batch of "Thousand Talents" national special experts of the Central Organization Department, the academician of the American Academy of Toxicology, and the CEO and chief scientist of Blu-ray Inno, Professor Kang Yujian, said that in the future, not only blood vessels, but also other organs of the human body can be printed in 3D. The disease-based pharmaceutical industry will turn to a people-oriented health industry." 30 rhesus monkeys implanted with 3D printed blood vessels More than 100 days later, still alive and kick "As of December 1, 2016, Blu-ray Yingnuo has performed 3D bioprinting in vivo implantation in 30 rhesus monkeys, and the survival rate of experimental animals is 100%." Kang Yujian told the reporter that the functional observation of the implanted blood vessel was taken after surgery. As of December 1, 2016, the structural and functional consistency observation of the implanted blood vessels of the experimental animals was observed from the shortest one day for up to 104 days. During the experimental period, all the experimental animals were differentiated into vascular tissues such as endothelial cells and smooth muscle cells after 3D bioprinting vascular implantation. After the 3D bioprinting blood vessel regeneration was completed, Its structure and function are consistent with the structure and function of the experimental animal's own blood vessels, and no abnormalities were found in the physiological indexes of the experimental animals. According to him, team researchers used 3D bioprint inks prepared from rhesus monkey autologous adipose-derived mesenchymal stem cells to construct bioactive artificial blood vessels using self-developed 3D biological blood vessel printing equipment, and replaced them with constant A rabbit's abdominal aorta. "The above experimental results are consistent with the original experimental expectations, and the printed materials are taken from the adipose-derived mesenchymal stem cells of the experimental animals, which ensures the safety of the blood vessel transplantation in vivo." Kang Yujian said. Animal experiments continue until May next year Huaxi Hospital issued a summary report It is reported that Blu-ray Inno was signed a technical development contract with the West China Hospital of Sichuan University in May 2016 for the 3D bioprinting vascular in vivo animal research experiment, and officially began the 3D bioprinting vascular animal experiment. The purpose of the experiment was to verify the structural and functional consistency of the 3D bioprinted blood vessels and the experimental animals' own blood vessels. The expected success indicators set by this animal experiment include 3D bio-printed blood vessels and experimental animals' autologous blood vessel replacement; 3D bio-printed blood vessels can be fused with experimental animals' autologous blood vessels; 3D bio-printed blood vessels are consistent with experimental animal autologous vascular structures and functions. The animal experiment was carried out at the Animal Experimental Center of West China Hospital of Sichuan University with GLP qualification. The experimental data is sufficient and has a staged summary report. It is reported that the animal experiment will continue until May 2017, and the standardization of the 3D bioprinting vascular graft procedure will be completed in the subsequent stage. After the experiment, the West China Hospital of Sichuan University issued an animal experiment summary report in accordance with the requirements of the 3D Bioprinting Vascular Endovascular Transplant Animal Experimental Research Technology Development Entrustment Contract. Professor Kang Yujian said: "The success of in vivo experiments in 3D bioprinting blood vessels has solved the problem of endothelialization of artificial blood vessels that have plagued clinical for half a century. At the same time, in vivo experiments have broken the need for adipose-derived mesenchymal stem cells to differentiate into vascular tissues. The understanding of a variety of cells." Kang Yujian stressed that the core concept of the technology is to maintain the dryness of stem cells without modifying the stem cells, by mobilizing the body's independent regeneration ability, to achieve the body's self-regulated tissue regeneration and functional recovery. This is a fundamental challenge to the current human cognition and differentiation of stem cells in stem cell research and application. Applicant clinical trial Entering the $15.8 billion cardiovascular disease market Blu-ray Inno 3D biovascular printing is mainly used in the field of cardiovascular diseases in the future. The incidence of cardiovascular disease is the highest in the world, and the market demand for vascular stents and artificial blood vessel replacement is huge. Currently, the main application in the cardiovascular field is non-biologically active artificial blood vessels or artificial stents. According to the World Health Organization, in 2012, the number of patients with cardiovascular and cerebrovascular diseases in the world exceeded 1.7 billion, accounting for about 25% of the global population. Peking University Research ("Interventional Device Classification and Trends", 2014) shows that in 2010, there were 3.33 million cases of global coronary surgery, and the global market for interventional cardiovascular disease treatment exceeded $15.8 billion and will be in 2018. More than $25.1 billion, the market has broad prospects. The Blu-ray Development Announcement, the next step, the company's 3D bio-printing blood vessels will apply to the relevant regulatory agencies for clinical trials, and further added that according to the results of animal experiments and related regulatory requirements, the company is writing, supplementing and improving clinical trial filings. Kang Yujian said that the move will have a revolutionary impact on the traditional medical market, which is a standardized pharmaceutical for disease classification, such as vascular disease treatment, which requires the patient to select the appropriate model for a limited number of artificial blood vessels, with the above technology Break through, through the patient's body three-dimensional image data, extract the patient's own fat as a 3D bioprint "ink", print out personalized blood vessels tailored for the patient. "The breakthrough in stem cell application technology will lead humans into the new era of tissue-manufacturing, organ-rejuvenating regenerative medicine and precision medicine. Blu-ray development pushes the "scientist + entrepreneur" model Improve the conversion rate of scientific and technological achievements Yang Lan, chairman of Blu-ray Yingnuo Holdings' parent company Sichuan Blu-ray Development Co., Ltd. (hereinafter referred to as “Blu-ray Developmentâ€), said: “Blu-ray development firmly promotes the 'scientist + entrepreneur' entrepreneurial innovation model, allowing scientists to do what scientists are good at, technology R&D, technological innovation; let entrepreneurs do things that entrepreneurs are good at, market expansion, business model innovation." According to the National Development and Reform Commission, China's scientific and technological achievements conversion rate is only 10%, far lower than 40% of developed countries. Yang Wei said: "As a corporate goal, we must incubate advanced scientific and technological achievements, but also let scientific and technological achievements go to market. Funds support scientific research, technology is transformed into market to realize income, only the two form a positive interaction, can healthy development According to some scientific and technological experts, private enterprises, as the main innovation unit of science and technology innovation, have institutional advantages such as flexible system and abundant incentive mechanism in promoting the transformation of scientific and technological achievements. As a representative of China's outstanding private enterprises, Blu-ray's investment in the life sciences is in line with the national entrepreneurial innovation policy. Blu-ray Yingnuo is a bio-tech company invested by Sichuan Blu-ray Development Co., Ltd. According to the Blu-ray development announcement, the company plans to invest 215 million yuan in the early stage for technology research and development and research team building. At the same time, the company has also established a partner mechanism, which will increase the capital of the company by the core personnel of Blu-ray Yingnuo. The total amount of capital increase is 16.15 million yuan. . According to the 2016 report of Blu-ray Development, the company has submitted 54 patent applications and obtained 12 rights; obtained 7 software copyrights; and obtained 68 trademark registration certificates. Kang Yujian introduced that 3D bioprinting with bio-brick technology as the core will be used in basic research (3D cell culture, embryology research, cell disease model), clinical application (cell therapy, induced tissue regeneration, induced angiogenesis), industrial application (Drug prediction, damage repair, regenerative medicine, repair, replacement of diseased tissues and organs) and other fields play a breakthrough role. Prefillable Syringe Series,Pre-Filled Flush Syringes,Coc&Cop Prefillable Syringes,Prefillable Syringes Shandong Qidu Pharmaceutical Co., Ltd. , https://www.qdyypharma.com